[18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour

#1381

Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.

Aim(s): To evaluate the correlation between FP and response to chemotherapy (CHT) and everolimus (E) for pancreatic NETs (PanNETs).

Materials and methods: Baseline and post-treatment imaging studies (contrast enhanced CT/MRI and FP) of 31 patients (P) treated for advanced, G1-2 PanNETs were retrospectively reviewed. A per lesion analysis was conducted, separately for each treatment arm (CHT and E), selecting up to 6 lesions (L) for each P. Baseline FP results (positive if SUV max > 3.5) and RECIST1.1 disease control rate (DCR) and objective response rate (ORR) were analyzed for possible correlations.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Ortolani S

Authors: Ortolani S, Cingarlini S, Citton E, Crosara S, De Robertis R,

Keywords: 18F-FDG-PET/CT, predictive, chemotherapy, everolimus, pancreatic NETs,

To read the full abstract, please log into your ENETS Member account.